Biostable aptamers with antagonistic properties to the neuropeptide nociceptin/orphanin FQ

  1. DIRK FAULHAMMER1,4,5,
  2. BERND ESCHGFÄLLER1,4,6,
  3. SANDRA STARK1,4,7,
  4. PETRA BURGSTALLER1,8,
  5. WERNER ENGLBERGER2,
  6. JEANNETTE ERFURTH1,9,
  7. FRANK KLEINJUNG1,10,
  8. JOHANNA RUPP3,
  9. SEBASTIAN DAN VULCU3,
  10. WERNER SCHRÖDER1,
  11. STEFAN VONHOFF1,
  12. HERMANN NAWRATH3,
  13. CLEMENS GILLEN2, and
  14. SVEN KLUSSMANN1
  1. 1NOXXON Pharma AG, 10589 Berlin, Germany
  2. 2Grünenthal GmbH, Molecular Pharmacology, 52078 Aachen, Germany
  3. 3Department of Pharmacology, Johannes Gutenberg Universität Mainz, 55101 Mainz, Germany

Abstract

The neuropeptide nociceptin/orphanin FQ (N/OFQ), the endogenous ligand of the opioid receptor-like 1 (ORL1) receptor, has been shown to play a prominent role in the regulation of several biological functions such as pain and stress. Here we describe the isolation and characterization of N/OFQ binding biostable RNA aptamers (Spiegelmers) using a mirror-image in vitro selection approach. Spiegelmers are l-enantiomeric oligonucleotide ligands that display high affinity and specificity to their targets and high resistance to enzymatic degradation compared to d-oligonucleotides. A representative Spiegelmer from the selections performed was size-minimized to two distinct sequences capable of high affinity binding to N/OFQ. The Spiegelmers were shown to antagonize binding of N/OFQ to the ORL1 receptor in a binding-competition assay. The calculated IC50 values for the Spiegelmers NOX 2149 and NOX 2137a/b were 110 nM and 330 nM, respectively. The competitive antagonistic properties of these Spiegelmers were further demonstrated by their effective and specific inhibition of G-protein activation in two additional models. The Spiegelmers antagonized the N/OFQ-induced GTPγS incorporation into cell membranes of a CHO-K1 cell line expressing the human ORL1 receptor. In oocytes from Xenopus laevis, NOX 2149 showed an antagonistic effect to the N/OFQ-ORL 1 receptor system that was functionally coupled with G-protein-regulated inwardly rectifying K+ channels.

Keywords

Footnotes

  • 4 These authors contributed equally to this work.

  • 5 Present addresses: Amersham Buchler GmbH & Co. KG, Fraunhoferstrasse 7, 85737 Ismaning, Germany;

  • 6 Novartis Pharma AG, WKL-490.1.55, 4002 Basel, Switzerland;

  • 7 Philogen S.r.l., La Lizza 7, 53100 Siena, Italy;

  • 8 P.B., Am Marktplatz 8, 82152 Planegg, Germany;

  • 9 Degussa AG, CVPH-BT, Rodenbacher Chaussee 4, 63457 Hanau-Wolfgang, Germany;

  • 10 MicroDiscovery GmbH, Marienburger Strasse 1, 10405 Berlin, Germany.

  • Article and publication are at http://www.rnajournal.org/cgi/doi/10.1261/rna.5186504.

    • Accepted November 7, 2003.
    • Received September 12, 2003.
| Table of Contents